These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10996630)

  • 41. Antibody-based vaccines for the treatment of melanoma.
    Lutzky J; Gonzalez-Angulo AM; Orzano JA
    Semin Oncol; 2002 Oct; 29(5):462-70. PubMed ID: 12407511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of dendritic-cell based prostate cancer vaccine.
    Tjoa BA; Murphy GP
    Immunol Lett; 2000 Sep; 74(1):87-93. PubMed ID: 10996633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melanoma vaccines: The problems of local immunosuppression.
    Polak ME; Borthwick NJ; Jager MJ; Cree IA
    Hum Immunol; 2009 May; 70(5):331-9. PubMed ID: 19405172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.
    Duperret EK; Liu S; Paik M; Trautz A; Stoltz R; Liu X; Ze K; Perales-Puchalt A; Reed C; Yan J; Xu X; Weiner DB
    Clin Cancer Res; 2018 Dec; 24(23):6015-6027. PubMed ID: 30262507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Yazdani M; Jaafari MR; Verdi J; Alani B; Noureddini M; Badiee A
    Immunotherapy; 2020 Apr; 12(5):333-349. PubMed ID: 32212934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour cell-based vaccines for the treatment of melanoma.
    Hsueh EC
    BioDrugs; 2001; 15(11):713-20. PubMed ID: 11707146
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?
    Tietze JK; Sckisel GD; Hsiao HH; Murphy WJ
    Int Rev Immunol; 2011; 30(5-6):238-93. PubMed ID: 22053969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melanoma vaccines.
    Yang JC
    Cancer J; 2011; 17(5):277-82. PubMed ID: 21952276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
    Dillman RO; Cornforth AN; Nistor GI; McClay EF; Amatruda TT; Depriest C
    J Immunother Cancer; 2018 Mar; 6(1):19. PubMed ID: 29510745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
    González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA
    J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine.
    Horvath JC; Horak A; Sinkovics JG; Pritchard M; Pendleton S; Horvath E
    Acta Microbiol Immunol Hung; 1999; 46(1):1-20. PubMed ID: 10331063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
    Greene JM; Schneble EJ; Jackson DO; Hale DF; Vreeland TJ; Flores M; Martin J; Herbert GS; Hardin MO; Yu X; Wagner TE; Peoples GE
    Cancer Immunol Immunother; 2016 Apr; 65(4):383-92. PubMed ID: 26894495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.